Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review

Hepatitis E is an acute self-limiting disease caused by hepatitis E virus (HEV). Recent reports show that HEV can induce chronic hepatitis or be reactivated in immunocompromised hosts. We report a 63-year-old woman with rheumatoid arthritis (RA) who developed hepatitis E during treatment with tocili...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeuchi, Hidekazu, Koinuma, Kana, Nakasatomi, Masao, Sakairi, Toru, Kaneko, Yoriaki, Maeshima, Akito, Yamazaki, Yuichi, Okamoto, Hiroaki, Mimura, Toshihide, Mochida, Satoshi, Nojima, Yoshihisa, Hiromura, Keiju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083553/
https://www.ncbi.nlm.nih.gov/pubmed/30147981
http://dx.doi.org/10.1155/2018/6873276
Descripción
Sumario:Hepatitis E is an acute self-limiting disease caused by hepatitis E virus (HEV). Recent reports show that HEV can induce chronic hepatitis or be reactivated in immunocompromised hosts. We report a 63-year-old woman with rheumatoid arthritis (RA) who developed hepatitis E during treatment with tocilizumab. Analysis of serially stocked serum samples confirmed that hepatitis was caused by primary infection with HEV and not by viral reactivation. Her liver function improved after discontinuing tocilizumab and remained within the normal range without reactivation of HEV for >5 years after restarting tocilizumab. We also reviewed the published cases of hepatitis E that developed during RA treatment.

Ejemplares similares